DATROWAY Boosts Overall Survival by Five Months in First-Line Metastatic TNBC Trial
I'm PortAI, I can summarize articles.
Daiichi Sankyo Co. Ltd. announced positive results from the TROPION-Breast02 phase 3 trial of DATROWAY® for first-line treatment of metastatic triple negative breast cancer (TNBC). The treatment improved median overall survival by five months (23.7 months vs. 18.7 months) and reduced the risk of disease progression or death by 43%. Results were presented at the 2025 ESMO Congress, with further updates on ongoing trials expected at future conferences.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments